Argenx expands use of Cradle’s AI antibody discovery platform

Argenx is expanding use of Cradle’s AI protein-engineering platform to more scientists and antibody discovery programs, Cradle announced on November 17. The expansion follows what the companies describe as successful initial work, although the announcement does not quantify those results.
According to Cradle, argenx scientists have used the platform both to improve existing leads and to generate new antibody candidates. The designs address multiple properties, including how strongly an antibody binds to its target and how selectively it does so.
The workflow moves through repeated rounds of design, testing and learning. Experimental results inform subsequent designs, while scientists can run the software independently and explore sequences beyond their original candidates. Argenx’s head of discovery, Bas Van Der Woning, said the company plans to apply that approach to additional programs.
The release does not disclose financial terms, the number of programs being added or clinical outcomes. Its significance is therefore an expansion of AI-assisted discovery inside an existing drug developer, rather than evidence that a new medicine works.
Sources and citations
Revision history
Published .